Evidence map›Paper›PMID 36466100›Full record

ReviewEuroasian journal of hepato-gastroenterology2022

Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist.

Reshu Khandelwal, Anuradha Supun Dassanayake, Shivaram Prasad Singh

Open access · diamondAbstract readReview
In one paragraph

Review in Euroasian journal of hepato-gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 81% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Reshu KhandelwalDepartment of Gastroenterology, Pushpawati Singhania Hospital and Research Institute, New Delhi, India.ORCID https://orcid.org/0000-0003-3541-8119
Anuradha Supun DassanayakeDepartment of Medicine, Colombo North Centre for Liver Disease, Faculty of Medicine, University of Kelaniya, Colombo, Sri Lanka.ORCID https://orcid.org/0000-0001-5567-3542
Shivaram Prasad SinghDepartment of Gastroenterology, SCB Medical College, Cuttack, Odisha, India.
University of Kelaniya · LKSriram Chandra Bhanja Medical College Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is one of the most prevalent metabolic diseases worldwide, causing an enormous burden on the economies of both developed and developing nations. Nonalcoholic fatty liver disease (NAFLD) is very closely associated with diabetes, and the two diseases are known to cause an increase in morbidity and mortality. Timely referral of a diabetic with NAFLD to a hepatologist can definitely delay disease progression and the related complications. Despite the magnitude, there are no guidelines that recommend a screening algorithm that must be followed for evaluating NAFLD in at-risk diabetics at the primary care level and their further referral to hepatologists. Nonalcoholic fatty liver disease management needs heightened awareness among primary care physicians/endocrinologists and hepatologists, and a collaborative care approach is paramount in these patients. Certain antidiabetic drugs are found to be beneficial in the treatment of NAFLD patients with diabetes, however, none of them are FDA approved. How to cite this article: Khandelwal R, Dassanayake AS, Singh SP. Nonalcoholic Fatty Liver Disease in Diabetics: The Role of Hepatologist. Euroasian J Hepato-Gastroenterol 2022;12(Suppl 1):S37-S40.

Indexed as

Antidiabetic drugsDiabetesFibrosisHepatologistNonalcoholic fatty liver diseaseNonalcoholic steatohepatitis

Identifiers

PMID36466100
PMCPMC9681571
OpenAlexW4297830723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.